Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danny Gibson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Health Estate|November 17, 2009
What can we learn from Italian lessons?Danny Gibson
International Journal of Chronic Obstructive Pulmonary Disease|September 15, 2018
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UKChris Kiff, Sandrine Ruiz, Nebibe Varol, et al.
Pharmacoeconomics - Open|August 28, 2024
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UKDanny Gibson, Neil Branscombe, Neil Martin, et al.
Respiratory Medicine|September 12, 2020
The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UKJ Mark FitzGerald, Sofie Arnetorp, Caitlin Smare, et al.
Rheumatology and Therapy|July 3, 2023
Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UKHeide A Stirnadel-Farrant, Sarowar M Golam, Barbara Naisbett-Groet, et al.
Thorax|September 18, 2017
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general populationMarjan Kerkhof, Trung N Tran, Joan B Soriano, et al.
Rheumatology and Therapy|July 3, 2023
Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UKHeide A Stirnadel-Farrant, Sarowar M Golam, Barbara Naisbett-Groet, et al.
Journal of Medical Economics|July 7, 2023
Cost-effectiveness of tezepelumab in Canada for severe asthmaMara Habash, Hannah Guiang, Irvin Mayers, et al.
Advances in Therapy|June 12, 2026
Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysisJoseph K Han, Joaquim Mullol, Claire Hopkins, et al.
BJGP Open|February 9, 2023
Healthcare costs associated with short-acting β<sub>2</sub>-agonists in asthma: observational UK SABINA studyDarush Attar-Zadeh, Toby Capstick, Deborah Leese, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Health Estate|November 17, 2009
What can we learn from Italian lessons?Danny Gibson
International Journal of Chronic Obstructive Pulmonary Disease|September 15, 2018
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UKChris Kiff, Sandrine Ruiz, Nebibe Varol, et al.
Pharmacoeconomics - Open|August 28, 2024
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UKDanny Gibson, Neil Branscombe, Neil Martin, et al.
Respiratory Medicine|September 12, 2020
The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UKJ Mark FitzGerald, Sofie Arnetorp, Caitlin Smare, et al.
Rheumatology and Therapy|July 3, 2023
Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UKHeide A Stirnadel-Farrant, Sarowar M Golam, Barbara Naisbett-Groet, et al.
Thorax|September 18, 2017
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general populationMarjan Kerkhof, Trung N Tran, Joan B Soriano, et al.
Rheumatology and Therapy|July 3, 2023
Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UKHeide A Stirnadel-Farrant, Sarowar M Golam, Barbara Naisbett-Groet, et al.
Journal of Medical Economics|July 7, 2023
Cost-effectiveness of tezepelumab in Canada for severe asthmaMara Habash, Hannah Guiang, Irvin Mayers, et al.
Advances in Therapy|June 12, 2026
Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysisJoseph K Han, Joaquim Mullol, Claire Hopkins, et al.
BJGP Open|February 9, 2023
Healthcare costs associated with short-acting β<sub>2</sub>-agonists in asthma: observational UK SABINA studyDarush Attar-Zadeh, Toby Capstick, Deborah Leese, et al.
Pageof 2